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Abstract
Introduction: Overexpression of the human epidermal growth factor receptor 2 (HER2) as a result of HER2 gene
amplification is associated with a relatively poor prognosis in breast cancer and is predictive of HER2-targeting
therapy response. False-positive rates of up to 20% for HER2 testing have been described. HER2-testing laboratories
are therefore encouraged to participate in external quality control schemes in order to improve HER2-testing
standardization.
Methods: This study investigated the feasibility of retesting large numbers of invasive breast cancers for HER2
status on tissue micro-array (TMA) as part of a quality control scheme. For this assessment different HER2 testing
methods were used including HER2 detecting antibodies SP3, 4B5, Herceptest and mono color silver in situ
hybridization (SISH) and dual color SISH. Final HER2 status for each tumor on the TMA was compared to the local
testing result for the same tumor. Discordances between these two results were investigated further by staining
whole tumor sections.
Results: For this study, 1,210 invasive breast carcinomas of patients treated in six hospitals between 2006 and 2008
were evaluated. Results from the three immunohistochemistry (IHC) and two in situ hybridization (ISH) assays
performed on the TMAs were compared. The final HER2 status on TMA was determined with SP3, 4B5 and mono
color SISH. Concordance between local HER2 test results and TMA retesting was 98.0%. Discordant results between
local and TMA retesting were found in 20 tumors (2.0%). False positive HER2 IHC results were identified in 13
(1.3%) tumors; false negative IHC results in seven (0.7%) tumors.
Conclusions: Retesting large volumes of HER2 classified breast carcinomas was found to be feasible and can be
reliably performed by staining TMAs with SP3, 4B5 and mono color SISH in combination with full-sized slides for
discordant cases. The frequency of false-positive results was lower than previously reported in the literature. This
method is now offered to other HER2-testing laboratories.
Introduction
Human epidermal growth factor receptor 2 (HER2) is a
member of the family of tyrosine kinase receptors. Over-
expression of the HER2 receptor generally results from
HER2 gene amplification and occurs in approximately
10% to 20% of primary breast carcinomas [1,2]. Positive
HER2 status of primary breast cancer has been asso-
ciated with relatively poor prognosis [3] and some stu-
dies have also shown that HER2 positive tumors differ
from HER2 negative tumors in their response to sys-
temic hormonal therapy [4] and chemotherapy [5,6].
Therapy with the monoclonal antibody trastuzumab tar-
gets the extra-cellular domain of the HER2 protein,
leading to receptor internalization and antibody depen-
dent cellular cytotoxicity [7,8]. Treatment with trastuzu-
mab was first shown to prolong survival in patients with
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HER2 positive metastatic breast cancer, especially when
combined with chemotherapy [9]. Adding trastuzumab
to adjuvant chemotherapy of patients with HER2 posi-
tive breast cancer was shown to improve patient survival
and reduce the chance of developing distant metastases
[10,11]. Lapatinib is an intracellular HER2 tyrosine
kinase inhibitor which has been approved for trastuzu-
mab-resistant HER2 positive metastatic breast cancer
[12,13]. As a result of these clinical findings, it has
become routine practice to test all invasive breast carci-
nomas for HER2 status. HER2 testing should be carried
out in such a way that false positive and false negative
test results are avoided in order to select the proper
patients for HER2 targeted therapies.
The HER2 status of a tumor can be assessed by var-
ious methods, several of which have been approved for
clinical use, including immunohistochemistry (IHC),
FISH, SISH and CISH (fluorescence, silver and chromo-
genic in situ hybridization). A 2007 report by an Ameri-
can Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) panel has estimated that 20%
of HER2 testing might be incorrect [14]. The panel
included several recommendations for improving HER2
testing variability and recommended that HER2-testing
laboratories show at least 95% concordance with vali-
dated HER2 negative and positive cases. Unfortunately,
published HER2 series have often found a significant
number of discordant results. Paik et al. retested tumors
treated with trastuzumab in the National Surgical Adju-
vant Breast and Bowel Project protocol 31 (NSABP-31)
trial which compared the addition of trastuzumab to
adjuvant chemotherapy [15]. Eligibility for this trial was
based on local HER2 test results, but it was estimated
that 18% of tumors were tested as false positive due to
inaccurate test and/or interpretation methods. Central
retesting of tumors locally tested as HER2 positive from
patients who participated in the N9831 trial identified
only 85.8% of tumors as HER2 amplified [16]. The same
study by Perez et al. also showed that the concordance
between local and central testing was found for FISH
(88.1%), Herceptest (81.6%) or other IHC methods
(75.0%). Fewer studies have described the frequency of
false-negative HER2 test results. O’Malley et al. reported
concordant results between 94.8% to 100% for IHC and
98.5% for FISH for all HER2 negative tumors [17].
These reported inaccurate results are explained by dif-
ferent protocols used in HER2 testing facilities. Factors
that affect test results include warm/cold ischemic time
of tissue, duration of fixation, used fixative, method for
antigen retrieval, antibody and test interpretation. In
order to improve the reliability and standardization of
HER2 results, laboratories are encouraged to participate
in external quality controls in order to improve the
standardization of HER2 testing. The study described
here was conducted to develop a rapid and reliable
method for the determination of false positive and false
negative HER2-testing rates in different pathology
laboratories. For this purpose, tissue blocks of HER2-
tested breast cancers were collected from six different
pathology laboratories and were used to create tissue
micro arrays (TMAs). Because this was the first TMA
assessment, different HER2 testing methods were used.
Results from these methods were compared in order to
determine which methods should be used for this and
future TMA assessments. The final TMA testing result
for each tumor was compared to the local testing result
to determine the reliability of the local HER2 methods
for each participating laboratory.
Materials and methods
TMA construction and IHC
Paraffin blocks from invasive primary breast carcinomas
diagnosed in 2008 were collected from the following
hospitals: Academic Medical Center (Amsterdam), Neth-
erlands Cancer Institute (Amsterdam), Diakonessenhuis
(Utrecht), Isala Klinieken (Zwolle), Leiden University
Medical Center (Leiden) and University Medical Center
(Groningen). Tumors from the Academic Medical Cen-
ter Amsterdam were from patients treated in 2006 and
2007. Patients from the Leiden University Medical Cen-
ter were treated between 2006 and 2008. Tissue blocks
that were used in this study were all acquired during
routine patient care. According to Dutch law, these can
be freely used after anonymizing the tissues, provided
these are handled according to national ethical guide-
lines (’Code for Proper Secondary Use of Human Tis-
sue’, Dutch Federation of Medical Scientific Societies).
An H & E stained section from each tumor was used to
identify an area with invasive breast cancer. From each
tumor three cores with thickness of 0.6 mm were col-
lected using the Beecher TMA instrument and inserted
in a donor block. Each donor block was stained with the
antibodies SP3 (Labvision, using Labvision autostainer,
Fremont, CA, United States), 4B5 (Ventana medical sys-
tems, using the Benchmark XT, Tucson, AZ, United
States) and Herceptest (DAKO, using Autostainer Link
48, DAKO, Glostrup, Denmark). Mono color and dual
color SISH was performed with the SISH kit obtained
from Ventana using the Benchmark XT.
HER2 evaluation on TMA
Scoring for IHC and in situ hybridization was performed
according to ASCO guidelines [14]. In brief, HER2 IHC
was scored as 0 when no tumor cells showed positive
HER2 membrane staining, 1+ scoring represented weak
partial staining of tumor cells (Figure 1), 2+ represented
weak to moderate intensity membranous staining of the
tumor cells (Figure 2) and 3+ staining represented
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strong circumferential staining of the tumor cells (Figure
3). For mono color SISH, the number of nuclear spots
was counted in 20 adjacent tumor cells. If the average
number of HER2 signals was six or more, the tumor
was scored as HER2 amplified and if the HER2 copy
number was < 6, the tumor was scored as HER2 non-
amplified. For dual color SISH, the number of spots in
20 adjacent cells was counted for HER2 signals and
chromosome 17 signals. When the ratio was < 1.8, the
tumor was scored as HER2 non-amplified. HER2 ampli-
fication was seen when the HER2 to chromosome 17
ratio exceeded 2.2. When the HER2 to chromosome 17
ratio was between 1.8 and 2.2, tumors were considered
equivocal. For the dual color SISH, the number of
nuclear copies of HER2 and chromosome 17 were sepa-
rately recorded as well. All three tumor cores were
scored separately. In case of discordance between the
cores, the highest score was used. When cores were
missing due to folding of material or loss of material
during the procedure, the highest scores from the
remaining core(s) were considered.
Data processing
Each TMA was scored by two pathologists. For 4B5, 51
(4.7%) out of 1,093 results showed a discrepancy
between two observers (Cohen’s  = 0.787). For SP3, 37
(3.4%) from 1,077 cases showed a discrepancy ( =
0.833). For Herceptest, 53 (4.8%) out of 1,107 cases
showed a discrepancy ( = 0.743). For 786 mono color
SISH cases, 22 results (2.8%) were discordant between
two observers ( = 0.838). For 914 dual color SISH
cases, 43 results (4.7%) were discordant between two
observers ( = 0.671). Significantly discrepant scores
between the two observers were reviewed by one obser-
ver (TD) to resolve the final score. In order to assess
the concordance between mono color and dual color
SISH, TMA results from all mono color and dual color
SISH tested tumors were compared. Tumors that were
equivocal on dual color SISH were not considered dis-
cordant with either HER2 non-amplified and HER2
amplified mono color SISH results for the same tumor.
All tumors that were discordant between mono and
dual color SISH were reviewed and scored again on the
Figure 1 TMA core displaying completely negative staining for HER2 (4B5 antibody). HER2, human epidermal growth factor receptor 2;
TMA, tissue micro-array.
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TMA. When discordant results existed between mono
color and dual color SISH, the IHC results from these
discordant tumors were evaluated. Results of the differ-
ent HER2-antibodies were evaluated by determining the
number of cases with discordant results between IHC
and mono color SISH: HER2 amplified tumors with 0 or
1+ scores on IHC (’false negative IHC’) and HER2 non-
amplified tumors with 3+ IHC scores (’false positive
IHC’). Positive predictive values were calculated as the
percentage of the total number of SISH amplified cases
for all 3+ IHC scores.
Comparison of HER2 score on the TMA and archival HER2
score
HER2 scores were retrieved from the pathology reports
supplied by participating centers. Four centers per-
formed HER2 testing on the surgical specimens. The
other two centers routinely performed HER2 testing on
the pre-operative core needle biopsies (CNB). For
almost all cases, the algorithm used to obtain a HER2
score was to perform IHC staining first. When 0 or 1+
staining results were observed, the tumor was regarded
as HER2 negative. A HER2 3+ score resulted in a HER2
positive score. However, the two centers that deter-
mined HER2 status on CNB also performed in situ
hybridization in case of a 3+ result. For all other centers,
in situ hybridization was performed only in the case of a
2+ result. If HER2 gene amplification was present, the
HER2 status was scored as positive. If no HER2 gene
amplification was detected, the HER2 status was scored
as negative. The final HER2 score on the TMA and the
HER2 scores from the report were compared for all
tumors. If there was a discrepancy in the HER2 score
between the TMA score and the score recorded in the
pathology report, a whole tissue block of the breast car-
cinoma was sectioned and used to perform additional
staining and in situ hybridization.
Results
Concordance between mono color and dual color SISH
A total of 1,210 invasive primary breast carcinomas were
included in this study. Complete mono color SISH and
Figure 2 TMA core displaying weak membranous HER2 staining (2+, 4B5 antibody). HER2, human epidermal growth factor receptor 2;
TMA, tissue micro-array.
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dual color SISH scores were obtained for 971 tumors.
The remaining 239 tumors had incomplete results, due
to folding of the core, loss of tumor material or insuffi-
cient amounts of invasive breast cancer for scoring.
Using mono color SISH, 881 tumors (91%) were non-
amplified (HER2 copy number < 6) and 90 (9%) tumors
were amplified (HER2 copy numbers > 6). For dual
color SISH, 833 tumors (86%) were non-amplified
(HER2 to chromosome 17 probe ratio < 1.8), 20 tumors
(2%) were considered equivocal for amplification (1.8 <
HER2 to chromosome 17 probe ratio < 2.2) and 118
(12%) tumors were amplified (HER2 to chromosome 17
probe ratio > 2.2). Thirty-two tumors were amplified
with dual color SISH while negative with mono color
SISH, and two were amplified with mono color SISH
but were negative for HER2 amplification with dual
color SISH. These 34 tumors were thus considered to
be discordant between mono color and dual color SISH.
Results from the 34 discordant tumors were revised. At
this repeated assessment, 11 tumors initially scored as
HER2 amplified with dual color SISH were scored as
negative for amplification, eight tumors were scored
equivocal for amplification and 11 tumors were again
scored as HER2 amplified. At repeated assessment of
mono color SISH results, two tumors that were initially
scored as negative for amplification were scored as
HER2 amplified and one tumor initially scored as posi-
tive was scored as HER2 negative. After this revision,
the number of discordant results was reduced to seven.
All these tumors were amplified with dual color SISH
(ratios were between 2.2 and 2.97) while no amplifica-
tion was found with mono color SISH. HER2 gene copy
numbers for these tumors with mono color SISH were
two (one case), three (five cases) or four (one case). We
compared the IHC results for these discordant cases,
and only one case showed 3+ staining for at least one of
the antibodies used when dual color SISH showed
HER2 gene amplification, but mono color SISH showed
no HER2 gene amplification. We decided to use the
revised mono color SISH results to determine HER2
Figure 3 TMA core displaying strong membranous HER2 staining (3+, 4B5 antibody). HER2, human epidermal growth factor receptor 2;
TMA, tissue micro-array.
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gene amplification for this HER2 TMA assessment.
Overall, correlation between these two SISH methods
when considering amplified and non-amplified tumors
was very high after revision (Table 1) ( = 0.952).
Comparison of the 4B5, SP3 antibodies with the
Herceptest
For comparing the performance of the three different
HER2 antibodies in detecting HER2 protein expression
on TMAs, only those cases were evaluated that had
both informative IHC and mono color SISH scores,
which resulted in over 1,000 interpretable cases for each
(Table 2). Performance of SP3, 4B5 and Herceptest anti-
bodies was evaluated based on the number of ‘false
negative’ results (0,1+ IHC score, positive for HER2
amplification with mono color SISH) and ‘false-positive’
results (3+ IHC score, negative for amplification with
mono color SISH). Both SP3 and 4B5 showed three
false-negative results (0.28% and 0.29%), while Hercept-
est showed 13 false negative results (1.2%). The number
of false-positive results was comparable (four tumors
with SP3, six with 4B5 and five with Herceptest). With
cases that were scored 3+ on IHC, positive predictive
values for the 4B5 and SP3 antibodies and the Hercept-
est were also comparable (93%, 95% and 93%, respec-
tively (Table 2). Concordance in staining between
antibodies was highest between the 4B5 and SP3 antibo-
dies ( = 0.770), compared to 4B5 and Herceptest ( =
0.707) and SP3 and Herceptest ( = 0.768) (Table 3).
TMA results
For 1,000 (82.6%) of all 1,210 cases, complete results
were obtained with 4B5, SP3, Herceptest and mono
color SISH. In 847 tumors of these cases (84.7%) no
HER2 protein overexpression was found with SP3, 4B5,
Herceptest (0 or 1+) or mono color SISH (HER2 copy
number < 6). Sixty tumors showed 3+ staining with all
three antibodies and HER2 gene amplification (6.0%).
For the remaining 93 complete cases, the final TMA
HER2 status was determined as follows: 65 tumors
(6.5%) showed 0, 1+ or 2+ IHC scores and were nega-
tive for HER2 gene amplification, and were thus judged
to be HER2 negative. Twelve tumors (1.2%) showed 3+
or 2+ IHC scores and were positive for HER2 gene
amplification and were thus judged to be HER2 positive.
For 16 cases (1.6%), there was a true discordance
between at least one of the antibodies mono color SISH
result (for example, 0/1+ IHC and HER2 gene amplifica-
tion; 3+ IHC and no HER2 gene amplification).
The most frequent discordant result between TMA
scores was a false-negative result with the Herceptest
(IHC score of 0/1+ with Herceptest and 2/3+ with SP3
and 4B5 and positive SISH) which occurred in eight
cases. Tumors stained with Herceptest frequently dis-
played prominent cytoplasmic and moderate but incom-
plete membranous staining (1+), while 4B5 and SP3
antibodies displayed complete membranous staining.
There were four cases for which all three antibodies
showed 3+ staining on TMA, while mono color SISH
did not detect HER2 gene amplification. Other discor-
dant results include 0/1+ staining with all three antibo-
dies while mono color SISH showed HER2 gene
amplification (three cases) and 3+staining with 4B5 and
Herceptest while SP3 and mono color SISH were nega-
tive (one case). When Herceptest results were omitted,
the number of interpretable cases for 4B5, SP3 and
mono color SISH increased to 1,020 and the number of
discordant results was reduced to eight (0.8%). In total,
932 tumors were HER2 negative and 80 tumors were
HER2 positive when determined with these three meth-
ods (Table 4). Therefore, the final HER2 status on TMA
was determined with SP3, 4B5 and mono color SISH.
Table 1 Mono color SISH versus dual color SISH.
Dual color SISH
Non-Amplified (ratio < 1,8) Equivocal (1,8 < ratio < 2,2) Amplified (ratio > 2,2)
Mono color SISH Non-Amplified (< 6 copy numbers) 841 24 7
Amplified (> 6 copy numbers) 0 2 88
SISH, silver in situ hydridization.













0,1+ 3 907 0,1
+
3 924 0,1+ 13 951
2+ 8 46 2+ 13 36 2+ 11 18
3+ 75 6 3+ 69 4 3+ 65 5
Total 86 959 85 964 89 974
HER2, human epidermal growth factor receptor 2; SISH, silver in situ hybridization.
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Comparison of local result with TMA result
For determining the concordance between local testing
result and the TMA retesting, we compared the HER2
scores listed in archival pathology reports from the local
centers with the final HER2 status determined by TMA
slides stained with SP3, 4B5 and mono color SISH.
Mono color SISH was used to determine HER2 status
on the TMA when IHC and mono color SISH were dis-
cordant. For 1,008 tumors, complete information was
available. We found discrepancies between the TMA
result and the result listed in the pathology report in 30
cases. In order to evaluate these cases further, all local
testing material was revised and full-sized slides were
stained with SP3, 4B5 and mono color SISH. When the
original HER2 gene amplification was initially deter-
mined on core needle biopsy, for our study these stains
were repeated on both biopsy and resected tumors.
Ten tumors with discordant results between TMA and
local result were found to be concordant after staining
full-sized slides. HER2 expression and gene amplification
was likely to be heterogeneously present in these
tumors, and the use of TMAs had led to a sampling
error. Thus, the total amount of discordant results
between local testing and this TMA testing was reduced
to 20. Total percentage of concordance for all pooled
cases from different centers was 98.0% (range 94.4% to
99.4%). Sensitivity and specificity for all centers com-
bined was 98.7% and 99.3%, respectively (Table 5).
Of the 20 discordant cases, 13 were scored as HER2
positive in local centers but were negative in our TMA
retesting (1.3% of the total of 1,008 cases) (Table 6).
Another seven cases were scored as HER2 negative in
local centers, but were positive upon retesting (0.7%)
(Table 7). For the 13 local positive results which were
negative with TMA retesting, seven of these had a local
3+ result, and six cases were found positive in local
laboratories due to 2+ IHC and amplification by ISH
methodology. The slides used for the original diagnosis
at the local centers were revised by a panel of patholo-
gists in order to assess local observer reliability. Four
tumors that were scored as 3+ in local hospitals were
scored as 2+ by the revision panel and thus reflect
observer inaccuracy. All local 2+ tumors were correctly
identified as 2+ on IHC. For two tumors, the local ISH
result was decided to be non-amplified by the revision
panel, while the local observer scored the tumor as
HER2 amplified.
For the remaining discordant cases, whole tumor
slides stained with SP3, 4B5 and mono color SISH were
evaluated in order to assess the reason for the discor-
dant result. For the 2+, ISH amplified results, complete
membranous staining on IHC could be reproduced with
the SP3 and 4B5 antibodies in all cases. The local ISH
results showed low level HER2 gene amplification (six
to ten) in four of six tumors and high level HER2 gene
amplification (> 10 copies) in two of six tumors, but all
were negative for amplification determined with mono
color SISH on both TMA and subsequent testing of the
whole tumor. These data indicate that the local IHC
result was reliable, but the reason for these results was
false-positive local ISH due to the ISH procedure. For
the remaining three local 3+ results, 3+ staining could
not be reproduced with SP3 and/or 4B5 antibodies on
TMA for two tumors and these were both negative for
gene amplification on mono color SISH on TMA and
on full-sized slides. For these tumors, the reason for dis-
cordance was the local IHC procedure leading to false 3
+ results. The remaining tumor was 3+ on local slides
and was also 3+ on SP3 and 4B5 stained slides, while
the mono color SISH result was non-amplified (two to
three copy numbers). This tumor thus likely represents
a case of protein overexpression without gene amplifica-
tion (Figure 4 and 5).
For all false-negative results, all seven local slides were
revised to assess observer performance. One of these
tumors was mistakenly interpreted as negative on IHC
while the tumor showed 2+ membranous staining in
parts of the tumor. The resulting six tumors were nega-
tive, but did show 2+ or 3+ results with 4B5 and SP3
Table 3 SP3, 4B5 and Herceptest.
SP3 Herceptest Herceptest
0,1+ 2+ 3+ 0,1+ 2+ 3+ 0,1+ 2+ 3+
4B5 0,1+ 911 15 0 4B5 0,1+ 920 7 0 SP3 0,1+ 930 9 0
2+ 30 26 1 2+ 42 15 0 2+ 27 18 2
3+ 1 7 72 3+ 7 8 68 3+ 6 3 66
Total 942 48 73 Total 969 30 68 Total 963 30 68
Table 4 HER2 status determined on TMA (SP3, 4B5 and
mono color SISH)
Total complete results 1,020 (84.3%)
Negative 932 (91.4%)
Positive 80 (7.8%)
Discordant results 8 (0.8%)
Incomplete results 190 (15.7%)
Total number of cases 1210 (100%)
HER2, human epidermal growth factor receptor 2; SISH, silver in situ
hybridization; TMA, tissue micro-array.
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stained slides, and amplification with mono color SISH.
This reflects an inaccurate local IHC procedure, which
resulted in false-negative results.
Discussion
Breast cancer is the most frequent form of cancer in
women with an incidence of 421,000 new cases in Eur-
ope in 2008 [18]. HER2 testing is considered the stan-
dard of care for all breast cancer patients as this can
determine neoadjuvant, adjuvant and metastatic treat-
ment. Due to the increasing demand for HER2 testing,
reliable HER2 testing methods are necessary. Earliest
reports into the concordance and reliability of local
HER2 tests revealed a significant amount of discordance
[15,16]. In order to improve the standardization of
HER2 testing, external quality controls have been devel-
oped in order to compare HER2 testing outcomes
between laboratories which can ensure that HER2 test-
ing leads to the same results irrespective of which
laboratory performs the HER2 test. Dowsett et al. pre-
sented the results from an international ring study that
sent 20 blank slides from a selection of HER2 amplified
and HER2 non-amplified breast cancer specimens from
one center to another, with each center performing both
IHC and FISH according to local methods [19]. Other
studies have created HER2 testing controls, specifically
designed to be used for the purpose of quality control
schemes. Rhodes et al. sent one slide containing four
cell line blocks with graded and constant HER2 protein
levels, two of these cell lines were previously diagnosed
as HER2 non-amplified and two were HER2-amplified
[20]. Slides were sent to 90 laboratories in 21 countries,
which all used their own methods for detecting HER2
protein expression and HER2 gene amplification [21].
These approaches allow the participation of high num-
bers of HER2 testing laboratories and allow for the iden-
tification of methods that lead to false-positive and false-
negative results. The downside of these methods is that
the number of tumors or cell lines tested in these stu-
dies was limited. The use of TMAs enables the use of
hundreds of different tumors in the same procedure by
analyzing one single TMA slide. The obvious downside
to this method is that using TMAs enables the analysis
of only limited amounts of tissue per tumor. However,
the analysis of two cores for HER2 status has been
shown to correlate with the whole-tumor sections in
more than 95% of cases [22]. We hypothesized that
TMAs might be used in retesting a high number of pre-
viously HER2-tested breast cancers. For this approach,
local testing centers would send a number of 100+
HER2 tested invasive breast cancers which would all be
included in the TMAs. The HER2 TMA result would be
Table 5 Performance of participating HER2 testing centers.




1 144 3 (2.1%) 2 (1.4%) 139 (96.5% 98.6 97.9
2 266 0 (0.0%) 2 (0.8%) 264 (99.2%) 99.2 100.0
3 158 1 (0.6%) 0 (0.6%) 156 (98.7%) 100.0 99.4
4 181 2 (1.1%) 2 (1.1%) 177 (97.8%) 98.9 98.9
5 90 0 (0.0%) 5 (5.6%) 85 (94.4%) 94.4 100.0
6 169 1 (0.6%) 2 (1.2%) 166 (98.2%) 98.8 100.0
Total 1,008 7 (0.7%) 13 (1.3%) 988 (98.0%) 98.7 99.3
HER2, human epidermal growth factor receptor 2.







TMA result Full-sized 4B5, SP3, monocolor-SISH
result
Conclusion
4 2+, ISH+ 2+, ISH+ No
amplification
2+, 2+, no amplification Local -ISH procedure unreliable
1 3+ 3+ No
amplification
3+, 3+ no amplification Overexpression without
amplification
2 3+ 3+ No
amplification
2+, 2+ no amplification Local IHC procedure unreliable
1 3+ 2-3+ No
amplification
2-3+, 2+, no amplification Local IHC scoring unreliable
3 3+ 2+ No
amplification
1-2+, 1-2+, no amplification Local IHC scoring unreliable
2 2+, ISH+ 2+, ISH - No
amplification
2+, 2 no amplification Local -ISH scoring unreliable
IHC, immunohistochemistry; ISH, in situ hybridization; SISH silver in situ hybridization; TMA, tissue micro-array.
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compared to the locally determined HER2 status in
order to assess the reliability. Because using TMAs
introduces the possibility of sampling error due to tissue
heterogeneity, discordant results would be decided by
testing whole tumor sections and revision of the local
slides that were used in the initial HER2 testing. This
method allows the assessment of the HER2 testing per-
formance in a relatively high number of tumors and the
identification of the local laboratory failure (either due
to HER2 staining evaluation or procedure). Using this
approach has the additional advantage that it uses
locally tested and treated tumors, possibly providing a
more reliable evaluation of HER2 testing performance
than when artificial cell lines are used. Because the
retesting results would be available to the local testing
center, this might also lead to information that might
benefit patients in future follow-up. In order to investi-
gate the feasibility of TMAs for HER2 testing quality
assessment, we have retested HER2 status in approxi-
mately 1,200 recently diagnosed breast carcinomas from
patients that were tested using various HER2 testing
reagents in six different pathology laboratories in the
Netherlands. Because this was a pilot study, the HER2
testing TMAs were stained with three different antibo-
dies and mono color SISH and dual color SISH in order
to ascertain optimal HER2 testing methods for the
Table 7 Local negative, TMA positive results (number = 7).
No. of cases Local result Revision local result TMA result Full-sized 4B5, SP3, monocolor-SISH result Conclusion
3 0+ 0+ Amplification 2+, amplification Local IHC procedure unreliable
3 0+ 0+ Amplification 3+, amplification Local IHC procedure unreliable
1 0+ 1-2+ Amplification 2+, amplification Local IHC scoring unreliable
Figure 4 Tumor that displayed HER2 protein overexpression in the absence of gene amplification (mono color SISH negative). HER2,
human epidermal growth factor receptor 2; SISH, silver in situ hybridization.
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purpose of this TMA evaluation. Mono color SISH and
SP3 and 4B5 antibodies were used to determine the
final HER2 status for the tumors on the TMA.
Based on the publications of ASCO/CAP, we hypothe-
sized that severe discrepancies between local results and
the TMA test would be found. However, in contrast to
our hypothesis, our results show unexpectedly high con-
cordance in each institution, indicating high reproduci-
bility and reliability of HER2 testing in these
laboratories. All these centers are hospitals with rela-
tively high-volumes of HER2 testing which increases the
reliability of testing results [17]. False negative test
results were identified in 0.7% of the cases and false
positive test results in only 1.3% of the cases. Reasons
for these 20 discordant cases were variable; four cases
were due to local inaccurate ISH assay procedures
(20.0%), two discordant cases were due to inaccurate
scoring of ISH assays (10.0%), eight were due to local
inaccurate IHC procedures (40.0%) and five were due to
inaccurate scoring of IHC assays (25.0%). The remaining
discordant case was a tumor with 3+ scores on local
IHC which tested 3+ with SP3, 4B5 and Herceptest, but
was negative with mono color SISH. Although several
studies have reported ISH negative tumors with 3+ IHC
results [23], these were generally all tested with a single
antibody, meaning that these discordant results could
reflect technical issues associated with HER2 testing.
Since this tumor has positive results with multiple anti-
bodies, this tumor is likely to indeed have overexpres-
sion of the HER2 protein in the absence of gene
amplification. Overexpression of the HER2 protein with-
out amplification at the genomic level has been
described previously to be rare [24].
FISH is traditionally considered the gold standard for
assessing HER2 gene amplification. Concordance between
locally and centrally performed FISH assays have been
shown to be higher compared to IHC [16]. Other probe-
based assays have been approved for clinical use, notably
CISH and SISH, which both use light-microscopy. The
advantage of light microscopy is that this allows
Figure 5 Tumor that displayed HER2 protein overexpression in the absence of gene amplification (3+, SP3 antibody). HER2, human
epidermal growth factor receptor 2.
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simultaneous evaluation of the invasive tumor component
and HER2 amplification. We have used mono color SISH
in our study as the gold standard. It has been previously
demonstrated that this method has very high concordance
with FISH [25]. We compared the concordance between
mono color and dual color SISH. Dual color SISH is only
considered amplified when the HER2 to chromosome 17
probe ratio exceeds 2.2. Importantly, loss of the chromo-
some 17 probe binding region can lead to a falsely elevated
HER2 to chromosome 17 ratio which is likely unrelated to
HER2 status. The recommendation is therefore not to
qualify any tumor as HER2 amplified unless there are at
least four HER2 copy numbers, regardless of the HER2/
chromosome 17 ratio. Secondly, for tumors with polysomy
17 and concomitant HER2 gene amplification, this ratio
will not exceed 2.2 and these tumors will thus be consid-
ered HER2 non-amplified. Since mono color SISH only
includes one probe for the HER2 gene, some polysomy 17
tumors will be considered HER2 amplified with this
method. Mono color SISH results are considered amplified
when the number of HER2 copies exceeds six. Some
authors have recommended that in the cases of four to six
HER2 spots on mono color SISH, dual hybridization
assays should be performed which might lead to identifica-
tion of some HER2 amplified tumors [26]. The concor-
dance and correlation between these mono color and dual
color SISH methods was high in our study We decided to
use mono color SISH for determining HER2 gene status
for this TMA assessment, since this seemed to correlate
better to IHC results for the few discordant cases.
We compared the characteristics of two monoclonal
rabbit antibodies, 4B5 and SP3, with the Herceptest, for
the assessment of HER2 protein expression on the
TMAs. Herceptest displayed the lowest sensitivity in our
study, as this antibody had the highest number of
tumors that tested 0 or 1+, but were positive for HER2
amplification on mono color SISH. This is in accor-
dance with another study comparing A0485, CB11,
TAB250 and the Herceptest, in which the Herceptest
was found to have the lowest sensitivity [27].
The 4B5 is a recently developed rabbit monoclonal
antibody which has been previously compared to the
CB11 antibody, the mouse monoclonal antibody that is
used in the FDA-approved PATHWAY kit (Ventana).
SP3 is another monoclonal rabbit antibody, which has
also been compared to the CB11 antibody [28] and
A0485, 4D5 CM-CB11 and Herceptest [29]. SP3 was
found to have a higher sensitivity than the Herceptest,
which is in accordance with our study.
Conclusions
In conclusion, we have shown that TMAs can be used
to evaluate the quality of HER2 testing in pathology
laboratories. This provides a reliable evaluation of HER2
testing performance. In the first assessment performed
in this way, we found HER2 testing sensitivity to be
98.7% and specificity to be 99.3%. As we have now
established this TMA-based evaluation in combination
with full-sized slides for discordant cases, we will also
offer this to other laboratories.
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